Clopidogrel (Iscover, Plavix) PBS listing extended to cardiac stent insertion

Published in NPS RADAR

Date published: About this date

Clinical content may change after this date. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment.

From 1 August 2009 clopidogrel can be prescribed in combination with aspirin as an authority (streamlined) benefit on the Pharmaceutical Benefits Scheme (PBS) after coronary artery stent insertion.1 Previously a PBS subsidy was available for the treatment of acute coronary syndrome (ACS), and for prevention of recurrence of ischaemic stroke, transient cerebral ischaemic events, myocardial infarction or unstable angina. The extended PBS listing allows patients who require a stent to have equitable access to clopidogrel therapy.

The Pharmaceutical Benefits Advisory Committee noted that there is evidence that prescribing clopidogrel, in combination with aspirin, is best clinical practice to prevent blood clots reforming after cardiac stent insertion.1

Clopidogrel was PBS listed for ACS on 1 February 2009. For further information refer to the March 2009 NPS RADAR In Brief Item: Clopidogrel PBS listing extended to include acute coronary syndrome (ACS) in combination with aspirin.


1. Australian Government Department of Health and Ageing. Public summary document for clopidogrel hydrogen sulfate, tablet 75 mg (base), Iscover, Plavix March 2009. Department of Health and Ageing - Clopidogrel hydrogen sulfate, tablet, 75 mg (base), Iscover®, Plavix®, March 2009 (accessed 14 July 2009).